[Asp371]-Tyrosinase (369-377), human |
| Catalog No.GC35014 |
La tyrosinase 369-377, humaine est un épitope restreint au HLA-A2.1 dérivé de la tyrosinase, a été utilisée pour développer des vaccins ciblant les tumeurs avec une efficacité mixte.
Products are for research use only. Not for human use. We do not sell to patients.
![[Asp371]-Tyrosinase (369-377), human Chemical Structure](/media/struct/GC3/GC35014.png "[Asp371]-Tyrosinase (369-377), human Chemical Structure")
Cas No.: 168650-46-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy[1][2].
[1]. Guillaume B, et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol. 2012 Oct 1;189(7):3538-47. [2]. Mitchell MS, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002 Feb 15;20(4):1075-86.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *